Fibroblast growth factor-21 and Visfatin as potential predictors for metabolic risk factors in obese children

被引:0
|
作者
Sahar A. El-Masry
Maisa Nasr Farid
Nayera E. Hassan
Muhammad Al-Tohamy Soliman
Lamis H Mekkawy
Galal Ismail Elashry
Safa N. Abd El-Fattah
机构
[1] National Research Centre,Biological Anthropology Department, Medical Research and Clinical Studies Institute
[2] Ain Shams University,Faculty of PostGraduate Childhood Studies
[3] National Research Centre,Clinical and Chemical Pathology Department, Medical Research and Clinical Studies Institute
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Fibroblast growth factor-21 (FGF-21) and Visfatin are associated with obesity. However; reviewing the literature; no studies were found to assess their role as potential markers for the metabolic disorders related to obesity in children. Assess the relations between serum FGF-21 and Visfatin with obesity and its metabolic disorders, and their use as potential predictors for metabolic risk factors in a sample of Egyptian obese children. This cross-sectional study included 111 Egyptian children (45 males and 66 females); aged 6–10 years to avoid the effect of puberty (prepubertal). The exclusion criteria (by full History taking and clinical examination) were the presence of any sign of puberty according to Tanner stage, the presence of identified causes of obesity (genetic syndromes, chromosomal or endocrinal disorders), chronic diseases (cardiovascular, gastrointestinal, and respiratory), or drug use like steroids; that would interfere with the type of obesity and affect the normal growth of the children. Also, any child with a BMI between 85 and 95th percentiles (overweight) was excluded from the study. All participating obese children were suffering from exogenous simple obesity. They were classified according to their body mass index (BMI) percentiles into 72 obese (BMI ≥ 95th), and 39 control non-obese ones (BMI > 15th to < 85th), based on the Egyptian Growth Charts for children and adolescents. Ethical approvals were granted from both the Ethics Committee of the “National Research Centre” and the “Faculty of Postgraduate Childhood Studies” (Approval No. 17/125). Also, informed written consent was taken from either of the parents and assent from the participating children. They were subjected to blood pressure assessment, anthropometric measurements (weight [Wt], height [Ht], BMI, waist [WC], and hip [HC] circumferences), and laboratory evaluation (Visfatin, FGF-21, LDL, HDL, TG, cholesterol, fasting glucose, insulin, and calculation of HOMA-IR). Mann–Whitney test and Spearman’s correlation test were applied. Obese children had significantly higher values than control ones regarding all the studied clinical (SBP, DBP), anthropometric parameters (Wt, Ht, BMI, WC, and HC), FBG, Insulin, HOMA-IR, Visfatin, and FGF-21, and had significantly lower values regarding HDL and Cholesterol. Among obese children, both FGF-21 and Visfatin had significant negative correlations with BMI and HC. At the same time, serum FGF-21 had a highly significant positive correlation with HDL. Visfatin and FGF-21 had highly significant positive correlations with each other. In the control group, both serum Visfatin or FGF-21 had insignificant correlations with each other and with all the studied clinical and anthropometric parameters. FGF-21 and Visfatin are related to the obesity markers, but they cannot be used as potential predictors for metabolic disturbance in obese prepubertal children; both had insignificant correlations with the metabolic risk factors.
引用
收藏
相关论文
共 50 条
  • [1] Fibroblast growth factor-21 and Visfatin as potential predictors for metabolic risk factors in obese children
    El-Masry, Sahar A.
    Farid, Maisa Nasr
    Hassan, Nayera E.
    Soliman, Muhammad Al-Tohamy
    Mekkawy, Lamis H.
    Elashry, Galal Ismail
    Abd El-Fattah, Safa N.
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [2] Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases
    Kharitonenkov, Alexei
    Shanafelt, Armen B.
    BIODRUGS, 2008, 22 (01) : 37 - 44
  • [3] Fibroblast growth factor-21: a metabolic regulator or something more?
    Salgado, Joao Victor
    Salgado, Bernardete Jorge
    CLINICAL ENDOCRINOLOGY, 2014, 81 (06) : 938 - 940
  • [4] Fibroblast Growth Factor-21 as a Therapeutic Agent for Metabolic Diseases
    Alexei Kharitonenkov
    Armen B. Shanafelt
    BioDrugs, 2008, 22 : 37 - 44
  • [5] Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasis
    Li, Shuai
    Jia, Haibo
    Liu, Zhihang
    Wang, Nan
    Guo, Xiaochen
    Cao, Muhua
    Fang, Fang
    Yang, Jiarui
    Li, Junyan
    He, Qi
    Guo, Rui
    Zhang, Teng
    Kang, Kai
    Wang, Zongbao
    Liu, Shijie
    Cao, Yukai
    Jiang, Xinghao
    Ren, Guiping
    Wang, Kai
    Yu, Bo
    Xiao, Wei
    Li, Deshan
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [6] Fibroblast growth factor-21 as a novel metabolic factor for regulating thrombotic homeostasis
    Shuai Li
    Haibo Jia
    Zhihang Liu
    Nan Wang
    Xiaochen Guo
    Muhua Cao
    Fang Fang
    Jiarui Yang
    Junyan Li
    Qi He
    Rui Guo
    Teng Zhang
    Kai Kang
    Zongbao Wang
    Shijie Liu
    Yukai Cao
    Xinghao Jiang
    Guiping Ren
    Kai Wang
    Bo Yu
    Wei Xiao
    Deshan Li
    Scientific Reports, 12
  • [7] The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
    Kharitonenkov, Alexei
    Wroblewski, Victor J.
    Koester, Anja
    Chen, Yun-Fei
    Clutinger, Cathleen K.
    Tigno, Xenia T.
    Hansen, Barbara C.
    Shanafelt, Armen B.
    Etgen, Garret J.
    ENDOCRINOLOGY, 2007, 148 (02) : 774 - 781
  • [8] Direct activation of the fibroblast growth factor-21 pathway in overweight and obese cats
    Brinker, Emily J. J.
    Towns, T. Jordan
    Watanabe, Rie
    Ma, Xiaolei
    Bashir, Adil
    Cole, Robert C. C.
    Wang, Xu
    Graff, Emily C. C.
    FRONTIERS IN VETERINARY SCIENCE, 2023, 10
  • [9] Circulating Fibroblast Growth Factor-21 and Risk of Metachronous Colorectal Adenoma
    Florea, Ana
    Harris, Robin B.
    Klimentidis, Yann C.
    Kohler, Lindsay N.
    Jurutka, Peter W.
    Jacobs, Elizabeth T.
    JOURNAL OF GASTROINTESTINAL CANCER, 2021, 52 (03) : 940 - 946
  • [10] Circulating Fibroblast Growth Factor-21 and Risk of Metachronous Colorectal Adenoma
    Ana Florea
    Robin B. Harris
    Yann C. Klimentidis
    Lindsay N. Kohler
    Peter W. Jurutka
    Elizabeth T. Jacobs
    Journal of Gastrointestinal Cancer, 2021, 52 : 940 - 946